

MIMIC-SR-ICD11: A Narrative-Driven Benchmark for Disease Prediction with Large Language Models

Anonymous ACL submission

Abstract

Early disease diagnoses can dramatically improve patient outcomes by enabling timely interventions, yet traditional approaches rely on laboratory and imaging data that require clinical visits and incur significant costs and delays. In this study, we introduce MIMIC-SR-ICD11 (MIMIC Self-Report with ICD-11), a dataset that transforms EHR discharge notes from the MIMIC database into first-person patient narratives and standardizes every diagnoses using WHO ICD-11 codes. We benchmark three leading large language models on overall accuracy (Hit @1 and F1 variants), sensitivity to candidate list length and ordering, and robustness across diseases of varying prevalence. Our experiments show that simply shortening the candidate list does not yield proportional gains in accuracy, and F1 scores even fall below a random-guess baseline. By splitting diseases into ten frequency-based groups, we uncover an unexpected accuracy dip for the most common conditions. To explain this phenomenon, we introduce two lexical specificity metrics: disease frequency–medical vocabulary size (DF-MVS) and medical term exclusivity score (MTES). These metrics demonstrate that generic, non-distinctive terminology drives prediction bias. To support future advances, we release our dataset as a standardized benchmark for the development of specialized medical diagnostic models.

1 Introduction

Disease diagnosis has become a central pillar of modern healthcare, enabling early detection and timely intervention for acute conditions, while also guiding lifestyle adjustments and medication regimens to prevent or slow chronic diseases. It is particularly valuable in resource-limited environments and helps individuals without medical expertise avoid a long search for the right provider.

More recently, large language models (LLMs) have demonstrated strong performance on clinical

question–answering benchmarks (Singhal et al., 2023, 2025). These models are typically fine-tuned on exam-style question–answer datasets designed for medical students (Jin et al., 2020; Pal et al., 2022; Jin et al., 2019), but their training regime does not directly translate to real-world diagnostic workflows, because these exam-style benchmarks present well-defined questions with fixed answer options, whereas real-world diagnosis involves interpreting ambiguous, multi-symptom narratives. Datasets designed for automatic diagnosis systems, such as DX (Wei et al., 2018) and DDX-Plus (Tchango et al., 2022), predict a patient’s underlying disease from categorical symptom indicators. However, this representation often obscures important clinical details; for example, reducing “severe, intermittent chest pain radiating to the left arm” to a simple present/absent flag loses key information about intensity and distribution. Moreover, because these collections are built for fixed-label classification, models trained on them cannot readily incorporate new symptoms or expand to additional disease categories beyond the original set. Su et al. (Su et al., 2024) introduced a dataset that uses patient-authored free-text symptom descriptions for automated disease prediction, but it is confined to Chinese data and leaves English self-reports unexplored.

To address these challenges, we introduce an English-language dataset, MIMIC-SR-ICD11, which converts EHR discharge notes into first-person patient self-reports and standardizes diagnoses using World Health Organization (WHO) ICD-11 terminology. We benchmark three leading LLMs (ChatGPT, Claude and Gemini) across three evaluation dimensions: overall predictive accuracy (Hit1 and Macro-/Micro-/Sample F1), sensitivity to candidate-list length and ordering, and robustness across diseases of varying prevalence. Our experiments reveal systematic positional bias in model decoding and a surprising performance decline for

085 the most frequent conditions. To explain this coun- 135
086 terintuitive result, we propose two lexical speci- 136
087 ficity metrics: disease frequency–medical vocabu- 137
088 lary size (DF–MVS) and medical term exclusivity 138
089 score (MTES), which together expose a vocabulary 139
090 bottleneck in high-frequency disease descriptions. 140
091 We publicly release our dataset and evaluation code 141
092 to support further research on narrative-driven di- 142
093 agnostic models. 143

094 2 Related Work 144

095 In recent years, several datasets have been released 145
096 to support the development of automatic diagnosis 146
097 systems. SymCat (Peng et al., 2018) synthesizes 147
098 records for 90 diseases and their associated symp- 148
099 toms by sampling according to disease–symptom 149
100 co-occurrence probabilities. DX (Xu et al., 2019) 150
101 and Muzhi (Wei et al., 2018) provide realistic, 151
102 multi-turn doctor–patient dialogues that closely 152
103 mirror actual clinical interactions. Building on 153
104 this work, DDXPlus (Tchango et al., 2022) adds 154
105 primary, differential, and final diagnoses alongside 155
106 binary, categorical, and multiple-choice symptom 156
107 representations. Although these benchmarks differ 157
108 in scale, they all reduce symptoms to fixed options, 158
109 which simplifies annotation and model training but 159
110 sacrifices descriptive richness and obscures subtle 160
111 clinical details. Moreover, by framing diagnosis 161
112 purely as a classification task that maps a rigid 162
113 symptom schema to a predetermined disease set, 163
114 they are ill suited for evaluating a language model’s 164
115 generative abilities in tasks such as predicting dis- 165
116 eases from free-text symptom descriptions. 166

117 To leverage the generative capabilities of large 167
118 language models, several recent corpora incorpo- 168
119 rate free-text symptom descriptions to enrich diag- 169
120 nostic datasets. These resources abandon fixed-slot 170
121 schemas and simple classification setups in favor of 171
122 capturing authentic clinical narratives within gen- 172
123 erative modeling frameworks. MSdiagnosis (Hou 173
124 et al., 2024) and CMEMR (Jia et al., 2025) combine 174
125 multi-section free-text narratives, covering chief 175
126 complaints, history of present illness, past medical 176
127 history, physical examination findings, and labo- 177
128 ratory results with structured labels for primary, 178
129 differential, and final diagnoses. Haodf (Su et al., 179
130 2024) mines unstructured patient self-reports from 180
131 the Haodf online platform to infer diagnoses di- 181
132 rectly, thereby reducing the time clinicians spend 182
133 navigating fragmented symptom communications. 183
134 Although these corpora significantly enhance the

expressiveness of symptom narratives and support 135
multi-step reasoning with generative models, they 136
are all Chinese-language datasets. To date, no 137
English-language corpus has been released that 138
leverages real-world, patient-authored free-text nar- 139
ratives for automated diagnosis. Another related 140
resource is ChatDoctor (Li et al., 2023), which 141
consists of multi-turn patient–doctor consultation 142
dialogues harvested from the HealthCareMagic¹ 143
platform. This dataset captures patients’ natural- 144
language symptom descriptions alongside physi- 145
cians’ follow-up questions and diagnostic advice. 146
Its design goal is to train medical dialogue systems 147
capable of generating plausible diagnostic recom- 148
mendations rather than performing precise disease 149
prediction. Although the conversations include 150
physicians’ inferences about the patient’s condi- 151
tion, these are expressed at a coarse level using 152
colloquial disease names that are neither standard- 153
ized nor mapped to a formal coding scheme (e.g., 154
ICD-10), limiting the dataset’s utility for evaluating 155
fine-grained diagnostic accuracy. 156

157 3 Data Construction 157

158 To enable low-cost, early-stage disease screening, 158
159 we focused our dataset on common conditions 159
160 that together account for over 80 percent of real- 160
161 world cases. We built the dataset on the latest 161
162 MIMIC-IV (Johnson et al., 2024) and MIMIC-IV- 162
163 Note (Johnson et al., 2022) releases. The construc- 163
164 tion pipeline consists of two steps. First, we extract 164
165 each admission’s diagnoses from MIMIC-IV and 165
166 normalize them to ICD-11 terminology. Second, 166
167 we retrieve free-text symptom descriptions from 167
168 the MIMIC-IV-Note EMR notes and rewrite them 168
169 as first-person patient self-reports. We release four 169
170 variants that differ in the number of disease cat- 170
171 egories, allowing evaluation across models with 171
172 varying capacity and deployment needs (see Ta- 172
173 ble 1 for statistics). 173

174 3.1 Disease Normalization 174

175 Since diagnostic codes in MIMIC-IV originate 175
176 from different versions of the International Classi- 176
177 fication of Diseases (ICD-9 and ICD-10), we stan- 177
178 dardized all disease labels to ICD-11 terminology 178
179 for consistency. We used the official ICD-11 API 179
180 provided by the WHO² to map diagnosis descrip- 180
181 tions to ICD-11 terms. 181

¹[\[www.healthcaremagic.com\]](http://www.healthcaremagic.com)(<http://www.healthcaremagic.com>)

²<https://icd.who.int/icdapi>

Dataset	Number of Samples	Avg \pm SD (Med, Min–Max) Tokens per Report	Avg \pm SD (Med, Min–Max) Diseases per Sample	Number of Disease Classes
MIMIC-SR-ICD11_2000	272,579	159.5 \pm 52.71 (152, 14 - 594)	2.81 \pm 1.73 (2, 1 - 43)	98
MIMIC-SR-ICD11_1000	282,996	159.9 \pm 53.03 (152, 14 - 594)	3.07 \pm 1.91 (3, 1 - 57)	173
MIMIC-SR-ICD11_500	288,767	160.06 \pm 53.15 (152, 14 - 594)	3.26 \pm 2.03 (3, 1 - 69)	275
MIMIC-SR-ICD11_200	295,281	160.2 \pm 53.25 (152, 14 - 594)	3.44 \pm 2.14 (3, 1 - 80)	498

Table 1: Statistics of dataset variants, where data_ N includes only diseases appearing at least N times. Tokens per report and diseases per sample are reported as Avg \pm SD (Median, Min–Max).

During the mapping process, we applied a subphrase matching strategy to handle excessively long or detailed diagnosis descriptions that often include causal or symptomatic elaboration and therefore fail to match directly against the WHO API. Specifically, when a full diagnosis description did not return a result, we extracted all contiguous subphrases of at least 80 percent of the original length, sorted them from longest to shortest, and queried each in turn until we obtained a valid mapping. This approach increased the likelihood of finding a relevant standardized concept for complex or verbose descriptions. To ensure high-precision normalization and minimize noise, we retain only ICD-11 entities marked as `important=True` by the WHO API, which indicates strong mapping confidence. We also exclude non-leaf codes (those with child subcategories) to prevent semantic overlap among disease labels. This filtering enhances consistency in both model training and evaluation and reduces label ambiguity.

3.2 Patient’s self-report generation

The MIMIC-IV-Note dataset provides de-identified free-text hospital records for each patient, which typically include a mix of symptom descriptions, examination results, medical history, and social background information. To derive patient-style narratives suitable for large language model reasoning, we utilized ChatGPT³(`gpt-4o-mini`) developed by OpenAI to convert these clinical notes into first-person self-reports. During this transformation, we explicitly instructed the model to filter out all clinician-generated content such as physical examination findings, diagnostic test results, and professional assessments, and retain only the subjective symptom descriptions as if recounted by the patient. The generated self-reports are written in natural language using complete sentences and framed from the patient’s perspective, which facilitates downstream disease diagnoses by aligning the

³<https://openai.com/api/>

input format with how patients typically describe their health concerns in real-world scenarios.

4 Experiment

To evaluate the diagnostic performance of state-of-the-art general-purpose LLMs, we conducted experiments with three widely used models: ChatGPT (`gpt-4o-mini`), Claude⁴ (`claude-3-7-sonnet-20250219`), and Gemini⁵ (`gemini-2.5-flash-preview-04-17`). Throughout our experiments, we employed the standardized prompt shown in Figure 1, which compels the models to select diagnoses exclusively from our candidate list. In addition to overall performance, we investigated how variations in the candidate disease list affect the quality of LLM prediction, focusing on changes in both the order and length of the candidate list. Finally, we analyzed the models’ performance across diseases of different prevalence levels to better understand their strengths and limitations.

User input: Analyze the patient’s description and identify the diseases that best match the reported symptoms, strictly selecting from the provided candidate list. Return only the names of the selected diseases, separated by semi colons. Do not include any reasoning or explanation.
Candidate list: [plasma cell myeloma, unstable angina, nontoxic single thyroid nodule, ...]. **Patient self-report:** "I am a male patient who has been experiencing persistent fevers, night sweats, and profound fatigue over the past few weeks. I have also noted significant weight loss, estimating around 15 pounds in the last two months. My energy levels have drastically decreased, to the point where I find it difficult to engage in any physical activity, and I have been sleeping excessively, averaging most of the day during a recent trip. Additionally, I have a persistent cough that is mostly unproductive and occasionally feels aggravated. I have had episodes of diarrhea, which included a possible bloody component. Throughout this time, I have been monitoring my symptoms closely, and my condition feels as though it is deteriorating."
Claude output: fever; gastrointestinal tract haemorrhage; weight loss nos; septicaemia

Figure 1: Illustration of the standardized prompt format (instruction, candidate list, and patient self-report) provided to the LLMs, together with a sample output from Claude.

⁴<https://docs.anthropic.com/en/api/overview>

⁵<https://ai.google.dev/gemini-api/docs/api-versions>

Model	Hit@1	Macro F1	Micro F1	Sample F1	Avg Pred Len	Valid Pred Rate
ChatGPT	0.2077 ± 0.0040	0.1727 ± 0.0038	0.1806 ± 0.0069	0.1630 ± 0.0070	2.7033 ± 0.0153	0.995 ± 0.0010
Gemini	0.1887 ± 0.0091	0.1510 ± 0.0034	0.1637 ± 0.0076	0.1549 ± 0.0092	3.9533 ± 0.0764	0.9981 ± 0.0004
Claude	0.2080 ± 0.0036	0.1492 ± 0.0021	0.1632 ± 0.0033	0.1546 ± 0.0054	3.5000 ± 0.0400	0.9603 ± 0.0040

Table 2: Performance comparison on disease prediction. “Avg Pred Len” denotes the average number of diseases predicted per sample. “Valid Pred Rate” indicates the proportion of model outputs that fall within the predefined candidate disease list, indicating how often the outputs conform to the candidate list.




Figure 2: Comparison of model performance under different candidate disease orders.

4.1 Overall Performance

We split MIMIC-SR-ICD11_2000 into 80% training, 10% validation, and 10% test sets. From the test set, we drew three random subsamples of 1,000 records each. We evaluated our models on each subsample and then calculated the mean performance and its standard deviation across the three runs. The result is shown in Table 2.

Standard deviations for all metrics remain below 0.01, indicating high consistency across the three independent 1,000-sample. In terms of Hit@1, both ChatGPT and Claude achieve approximately 0.208, comfortably ahead of Gemini’s 0.189. ChatGPT also leads on Macro, Micro, and Sample F1 scores. We attribute this to its more conservative strategy, favoring high-confidence diagnoses and producing shorter prediction lists. In contrast, Gemini and Claude generate longer lists to maximize recall, but this comes at the expense of F1 score. Finally, ChatGPT and Gemini strictly follow the candidate list provided, each with a Valid Pred Rate greater than 99%, while Claude’s rate is slightly lower at 96%, indicating occasional out-of-list predictions.

4.2 Disease Order Effect

In this section, we investigate the robustness and stability of LLMs performance between different disease orders in the candidate list. Specifically, we design five schemes: 1) Origin is a random order but fixed for every sample prediction; 2) Ran-

dom shuffles the candidate list for each sample; 3) Freq-First follows the real disease-frequency distribution (highest to lowest); 4) Correct-First places the ground-truth label at the front of the list; 5) Correct-Last places the ground-truth label at the end of the list. The result is shown in Figure 2.

As illustrated in the figure 2, varying the candidate list order produces a consistent effect across all LLMs: Correct-First ordering reliably achieves the highest performance, while Correct-Last ordering consistently produces the lowest. The superior performance of the Correct-First ordering can be largely attributed to the positional bias inherent in transformer-based LLMs. These models assign disproportionately higher attention weights to tokens that appear early in the input sequence, making them more likely to influence the output distribution. Comparing across LLMs, ChatGPT experiences the greatest boost under Correct-First ordering, with Hit@1 rising from around 0.2 to over 0.34. Gemini and Claude also benefit, each gaining about ten points in Hit@1, increasing from roughly 0.22 to around 0.32. This indicates that ChatGPT may be the most susceptible to positional cues but also the most capable of leveraging them when the correct label is highlighted. In contrast, Claude’s performance drop under Correct-Last is the steepest among the three, confirming that it relies more heavily on early-positioned tokens.

Beyond these extreme cases, we also observe that ordering by global frequency (“Freq-First”)

Model	Candidate List	Hit@1	Macro F1	Micro F1	Sample F1	Avg Pred Len	Valid Pred Rate
ChatGPT	Long List	0.210	0.1750	0.1885	0.1703	2.70	0.9963
	Short List	0.200	0.1738	0.1866	0.1673	3.06	0.9311
	Δ	-4.76%	-0.69%	-1.01%	-1.76%	-	-6.54%
Gemini	Long List	0.199	0.1507	0.1725	0.1654	3.97	0.9977
	Short List	0.197	0.1703	0.1899	0.1750	4.71	0.9518
	Δ	-1.01%	+13.01%	+10.09%	+5.80%	-	-4.60%
Claude	Long List	0.199	0.1507	0.1725	0.1654	3.97	0.9977
	Short List	0.205	0.1761	0.1943	0.1807	4.17	0.9451
	Δ	+3.02%	+16.85%	+12.64%	+9.25%	-	-5.27%

Table 3: Comparison between using long candidate lists and short candidate lists for disease prediction. Δ row shows the percentage change from the long list to the short list for each metric.

consistently improves over both the fixed original order and the per-sample random shuffle. This suggests a lightweight heuristic for boosting performance: listing candidates in decreasing prevalence can give the model a small but reliable edge, even without access to the true label. Notably, the gain from Freq-First is most pronounced for Hit@1, where accuracy rises by roughly 2–3 points all models.

Finally, we see that F1 metrics are relatively stable across ordering schemes compared to Hit@1. The divergence between the best and worst ordering for Macro and Sample F1 remains under 5 points for all models, whereas Hit@1 swings by over 15 percents. Because Hit@1 measures only the model’s first choice, moving the true label out of the top slot causes Hit@1 to drop to zero. By contrast, F1 scores consider the full set of returned labels. Consequently, F1 metrics mitigate the impact of candidate list reordering, whereas Hit@1 remains highly sensitive to even slight shifts in label position.

4.3 Candidate Length Effect

We aim to test whether LLMs can distinguish the correct diagnoses when faced with high-confidence distractors in a compact candidate list. To this end, we first gather the false positive predictions from the models produced under the Freq-First and Correct-First orders. Because the models achieve their strongest performance under these two orders and the incorrect labels predicted by the models tend to assign high confidence score. We then insert the true diagnoses into this pool of confusable options. This process yields a shortlist that averages 10.45 diseases per case, allowing us to assess each model’s ability to reject misleading choices. The results are summarized in Table 3

First, we observe that the Valid Pred Rate decreases for all models. The short candidate list contains each model’s false positives, some of which fall outside the original candidate list. These invalid but confident distractors lower the Valid Pred Rate and force the models to cover more diseases than they did with the long list.

Second, shortening the candidate list yields clear gains for both Gemini and Claude. Gemini’s F1 rises sharply simply because there are fewer distractors to sift through, but it still falls short of the other two models. However, the comparative performance of ChatGPT and Claude remains inconclusive. Claude outperforms ChatGPT on every metric, but part of this advantage may stem from its prediction length rather than from deeper diagnostic insight. Specifically, our shortlists contain an average of 10.45 diseases per case, with roughly three true labels. Randomly selecting four candidates from such a list yields a higher expected F1 score than selecting only three, since the extra pick increases the probability of covering a true label without substantially lowering precision. In practice, Claude outputs 4.17 labels on average, a tendency that artificially boosts its F1 even under near-random selection. ChatGPT, by contrast, returns fewer labels and therefore does not derive the same statistical benefit. This artifact explains why Claude appears to gain more from list reduction than ChatGPT, despite both models accessing the exact same information.

Finally, while these LLMs can easily exclude unlikely diseases, they struggle to distinguish among highly confusable conditions. Under a random-guess baseline on the short list, the expected sample F1 is approximately 0.30, yet all models perform well below this threshold. This

gap highlights the need for stronger fine-grained diagnostic discrimination.

4.4 Performance in frequent and infrequent diseases

4.4.1 Counterintuitive Frequency Effects

We partitioned our 98 diseases into ten prevalence-based groups and evaluated models’ accuracy within each group. Groups 1 through 9 each contain ten diseases sorted by descending frequency, while Group 10 comprises the eight rarest conditions. Figure 4 shows performance for each model under two candidate list ordering schemes: one arranged by global frequency (Freq-First) and the other randomly shuffled.

We find that LLMs do not exhibit a simple "frequency bias". Their Macro F1 scores across disease-frequency groups do not mirror the underlying data skew: rare conditions are not disproportionately more difficult to predict than common diseases. In fact, the decrease in Macro F1 from high- to low-frequency groups is much smaller than the corresponding drop in sample counts. This pattern is made more striking by a counterintuitive dip in performance on the very highest-frequency diseases (Group 1). Surprisingly, Group 1 yields lower F1 scores than Groups 2–4. Moreover, in classical imbalanced-label settings, models tend to overgenerate frequent labels, boosting recall at the expense of precision. In contrast, LLMs exhibit the opposite trend: for the highest-frequency group, precision markedly exceeds recall, whereas for the rarest groups, recall outstrips precision.

4.4.2 Mechanisms Behind Frequency Bias

Our first attempt employed a simple Document-Frequency–Vocabulary Size (DF–VS) metric, defined as

$$\text{DF-VS}_d = \frac{|V_d|}{\text{DF}_d} \quad (1)$$

where DF_d is the number of reports mentioning disease d and V_d the set of unique vocabularies used to describe it. Although low DF–VS correlates with poorer prediction (since a smaller, less diverse vocabulary makes discrimination harder), DF–VS alone does not fully account for the pronounced performance drop on the most frequent diseases. To uncover the additional factors behind this counterintuitive effect, we introduce two refined metrics, Frequency–Medical Vocabulary Size (DF–MVS) and Medical Term Exclusivity Score (MTES). Below, we define each metric formally.

Disease Frequency–Medical Vocabulary Size (DF–MVS) We denote by M_d the number of distinct medical terms appearing in all free-text reports for the disease d . The DF–MVS metric then captures the average term richness per document:

$$\text{DF-MVS}_d = \frac{M_d}{\text{DF}_d}. \quad (2)$$

Here, M_d is obtained by extracting all unique medical-entity mentions from reports of disease d , and DF_d is the total count of those reports. This metric captures both how often a disease appears and the breadth of specialized vocabulary used to describe it. Lower DF–MVS indicates that the description of a disease has fewer medical terms.

Medical Term Exclusivity Score (MTES) For each term $t \in V_d$, let $\text{freq}_{d'}(t)$ be the frequency of t in reports of the disease d' , and let D be the total number of diseases. We first compute the average cross-disease frequency of t :

$$\overline{\text{freq}}_{-d}(t) = \frac{1}{D-1} \sum_{d' \neq d} \text{freq}_{d'}(t). \quad (3)$$

Then MTES is defined as the mean of the reciprocal of these averages (plus a small constant ϵ to avoid division by zero):

$$\text{MTES}_d = \frac{1}{|V_d|} \sum_{t \in V_d} \frac{1}{\overline{\text{freq}}_{-d}(t) + \epsilon}. \quad (4)$$

Lower MTES values indicate that a disease’s terms are rarely shared with others, reflecting higher descriptive specificity.

To calculate DF–MVS and MTES metrics, we employ spaCy’s Bio-medical NER model (en_ner_bc5cdr_md) (Gu et al., 2017) to extract clinical entities from free-text reports. This model has been fine-tuned on the BioCreative V CDR corpus (Li et al., 2016), which provides extensive, high-quality annotations for both disease and chemical mentions in biomedical literature. Compared to general-purpose NER systems, it offers superior precision and recall on medical terminology, ensuring robust recognition of both common and rare conditions.

As shown in Figure 4, although Group 1 diseases account for more than 40 percent of the dataset, they remain among the most difficult to predict for three closely linked reasons. First, Group 1 registers the lowest DF–VS values (Figure 4.a). This indicates that despite their high frequency, these

Group	1	2	3	4	5	6	7	8	9	10
Proportion (%)	43.49	17.83	9.64	6.98	5.50	4.45	3.82	3.24	2.93	2.13

Table 4: Sample Proportions in Each Disease-Prevalence Group (High-to-Low Frequency Order)




Figure 3: Performance across different frequency groups of diseases. Higher-frequency diseases tend to be predicted with greater accuracy, indicating a correlation between disease frequency and model performance.

470 diseases are described using a small, generic set of
471 terms, which limits the richness of their lexical rep-
472 resentation. Second, Group 1 also scores poorly on
473 DF-MVS (Figure 4.b). In practice, this means that
474 even though there is abundant text, very few of the
475 tokens are truly informative medical words such as
476 specific biomarkers, nuanced symptom qualifiers,
477 or disease-defining expressions. As a result, nar-
478 rative redundancy prevails with repeated mentions
479 of terms such as pain or fever, depriving the model
480 of the high-signal features it needs. Third, Group
481 1 has the lowest Medical Term Exclusivity Score
482 (Figure 4.c). The few medical terms that appear
483 are common across many conditions, so they carry
484 little mutual information with any single diagno-
485 sis. Together, these factors create a vocabulary
486 bottleneck: a small, non-exclusive set of terms that
487 produces a low signal-to-noise ratio and prevents
488 the model from learning the distinctive patterns
489 required for accurate prediction.

490 By contrast, mid-frequency diseases in Groups
491 2 occupy an optimal range. They appear often
492 enough to accumulate varied phrasing yet remain
493 uncommon enough to invoke specific medical de-
494 scriptors, and this balance raises their DF-MVS
495 while lowering their MTES. Rare diseases in
496 Groups 7 to 10 suffer from small sample sizes
497 but benefit from highly distinctive labels such as
498 "alopecia areata" or "Wegener's granulomatosis",
499 which help the model form clear decision bound-
500 aries. Therefore, mid-frequency and rare disease
501 categories tend to become easier for the model to
502 predict simply by adding more examples, because
503 the language used to describe them already con-

504 tains distinct, high-signal terms. In contrast, adding
505 or reducing additional samples for very common
506 diseases does little to help, since their narratives
507 rely on broad, generic words that volume changing
508 alone cannot diversify.

509 To break through this plateau for frequent condi-
510 tions, we need to deliberately expand the linguistic
511 palette in their documentation. Pulling synonym
512 lists from established medical vocabularies can in-
513 ject subtle variations in how symptoms and findings
514 are named. Paraphrase-driven templates can recast
515 identical clinical observations in different phras-
516 ings, teaching the model to recognize conceptually
517 equivalent expressions. Enhanced entity recogni-
518 tion can spotlight less obvious but diagnostically
519 relevant terms buried in the text. Together, these
520 efforts would boost the uniqueness and richness of
521 the textual features, giving the model the nuanced
522 cues it needs to distinguish among common disease
523 labels. In addition to enriching narrative descrip-
524 tions, we must acknowledge that some conditions
525 simply lack highly distinctive symptoms and are
526 only definitively diagnosed through laboratory tests
527 or imaging studies. For these diseases, model in-
528 puts should be augmented with structured findings
529 such as key lab values, radiology impressions or
530 vital signs. Finally, we can improve prediction
531 safety and focus by adopting a severity-weighted
532 candidate checklist. Rather than treating all disease
533 classes equally, the system can estimate each con-
534 dition's potential impact on patient outcomes (e.g.,
535 risk of organ failure or mortality) and elevate high-
536 consequence diagnoses into the shortlist even when
537 their textual signatures are subtle. This risk-aware




Figure 4: Analysis of disease prevalence and vocabulary specificity across prevalence groups. (a) Proportion of samples in each disease-frequency decile (Group 1 = most frequent, Group 10 = rarest). (b) Average Document-Frequency–Medical Vocabulary Specificity (DF–MVS) per group, illustrating that rarer diseases employ more distinctive medical terms. (c) Average Medical Term Exclusivity Score (MTES) per group, indicating how uniquely each group’s terminology appears compared to the rest. A high DF–MVS coupled with a low MTES signifies that the group’s medical vocabulary is both plentiful and uniquely characteristic.

ranking ensures that life-threatening conditions receive appropriate attention, balancing linguistic uncertainty with clinical urgency and further reducing the chance that a common but dangerous disease is overlooked.

5 Conclusion

In this work we have introduced a new benchmark for narrative-driven disease prediction. We convert MIMIC electronic health record notes into first-person patient self-reports and normalize all diagnoses to ICD-11 name. With the proposed MIMIC-SR-ICD11 dataset, we evaluate three leading large language models (ChatGPT, Claude and Gemini) on overall accuracy, sensitivity to candidate list ordering and length, and robustness across disease prevalence groups.

Our experiments reveal several important insights. First, LLMs performance depends strongly on how candidate diseases are presented. LLMs exhibit positional bias when disease lists are permuted and benefit from shorter, more focused candidate sets only under certain conditions. Second, common diseases prove surprisingly difficult to predict despite their data abundance. We show that this difficulty arises from a vocabulary bottleneck: high-frequency conditions are documented with generic and non-exclusive terms that offer low signal to the model. Mid-frequency and rare diseases by contrast gain more from increased sample size because their narratives already contain distinctive terminology.

6 Future Work

In the future, we identify three key directions for advancing narrative-driven disease prediction:

1. Incorporate Chain-of-Thought Inference. We will augment our dataset with explicit reasoning traces by prompting LLMs to generate intermediate “chain-of-thought” inference. This can guide models to attend to critical symptom-to-diagnoses links and improve interpretability, helping to surface latent clinical cues that raw text alone may obscure.

2. Train a Domain-Specialized Diagnostic LLM: We will fine-tune a compact model that has been pretrained on a large medical text corpus using our MIMIC-SR-ICD11 dataset. Training will include a reinforcement learning objective that rewards outputs matching our curated candidate list and penalizes any predictions outside this set. After fine-tuning, we will reassess the frequency bias to determine whether this approach improves prediction performance across both common and rare disease categories.

3. Enable hierarchical disease prediction with ICD-11 code We will leverage the built-in hierarchy of ICD-11 to produce predictions at multiple levels of granularity. For each specific code it predicts such as “Type 2 diabetes mellitus”, it will also identify its parent categories (such as, “diabetes mellitus”). This layered output gives downstream applications the flexibility to adjust their decision scope. Downstream applications can then choose whether to act on broad disease classes for initial screening or on detailed leaf-level codes for precise diagnoses.

Together, these enhancements will deepen model reasoning, tailor performance to the diagnostic domain, and provide clinicians with both detailed and overview predictions across the disease hierarchy.

607	A License and Availability	C Ethics	650
608	All of our code and the MIMIC-SR-ICD11 dataset	All human-subject data in this study (MIMIC-IV	651
609	are released under the Creative Commons Attribution	and MIMIC-IV-Note) are fully de-identified under	652
610	4.0 International (CC BY 4.0) license. The full	HIPAA and were released under a PhysioNet	653
611	text of the CC BY 4.0 license is available at https://creativecommons.org/licenses/by/4.0/ .	Data Use Agreement (DUA) that mandates human-	654
612		subjects training and forbids any attempt at re-	655
613	B Artifact Usage and Intended Use	identification. The original IRBs at Beth Israel	656
614		Deaconess Medical Center and MIT approved the	657
615	B.1 Use of Existing Artifacts	data release with a waiver of informed consent and	658
616	We relied on several third-party resources, each	determined that secondary analyses of these de-	659
617		identified records are exempt from ongoing review.	660
618		Our usage strictly adheres to these terms and re-	661
619		mains within a research-only context. The patient	662
620		self-reports we generate via ChatGPT are synthetic	663
621		paraphrases of those de-identified notes and con-	664
622		tain no additional private information, so no new	665
623		consent is required.	666
624		D Acknowledgements	667
625		We used ChatGPT (gpt-4o-mini) as a writing assis-	668
626		tant to help polish sentence structure and improve	669
627		readability. All technical content, analyses, and	670
628		conclusions were developed solely by the authors.	671
629		E Limitations	672
630		Despite its contributions, our work has several im-	673
631		portant limitations.	674
632		Synthetic self-reports Our patient narratives are	675
633		generated by prompting ChatGPT to paraphrase	676
634		de-identified discharge text. Although we care-	677
635		fully instructed the model to retain only subjective	678
636		symptom language, this process may introduce ar-	679
637		tifacts, omit subtle nuances, or diverge from how	680
638		real patients describe their own experiences. Future	681
639		work should validate our synthetic reports against	682
640		authentic patient-provided narratives.	683
641		ICD-11 mapping We rely on subphrase match-	684
642		ing to map heterogeneous ICD-9/10 descriptions	685
643		to ICD-11 concepts via the WHO API. While this	686
644		increases coverage, it may still produce incorrect	687
645		or overly broad mappings for very complex diag-	688
646		nos. Mis-mappings could propagate noise into	689
647		both training and evaluation.	690
648		References	691
649		Jinghang Gu, Fuqing Sun, Longhua Qian, and Guodong	692
		Zhou. 2017. <i>Chemical-induced disease relation ex-</i>	693
		<i>traction via convolutional neural network. Database,</i>	694
		2017:bax024.	695

696	Ruihui Hou, Shencheng Chen, Yongqi Fan, Lifeng Zhu, Jing Sun, Jingping Liu, and Tong Ruan. 2024. Msdiagnosis: An emr-based dataset for clinical multi-step diagnosis. <i>arXiv preprint arXiv:2408.10039</i> .	752
697		753
698		754
699		755
700	Mingyi Jia, Junwen Duan, Yan Song, and Jianxin Wang. 2025. medIKAL: Integrating knowledge graphs as assistants of LLMs for enhanced clinical diagnosis on EMRs. In <i>Proceedings of the 31st International Conference on Computational Linguistics</i> , pages 9278–9298, Abu Dhabi, UAE. Association for Computational Linguistics.	756
701		757
702		758
703		759
704		760
705		761
706		762
707	Di Jin, Eileen Pan, Nassim Oufattole, Wei-Hung Weng, Hanyi Fang, and Peter Szolovits. 2020. What disease does this patient have? a large-scale open domain question answering dataset from medical exams. <i>arXiv preprint arXiv:2009.13081</i> .	763
708		764
709		765
710		766
711		767
712		768
713	Qiao Jin, Bhuwan Dhingra, Zhengping Liu, William W. Cohen, and Xinghua Lu. 2019. Pubmedqa: A dataset for biomedical research question answering. In <i>Proceedings of the 2019 Conference on Empirical Methods in Natural Language Processing and the 9th International Joint Conference on Natural Language Processing (EMNLP-IJCNLP)</i> , pages 2567–2577.	769
714		770
715		771
716		772
717		773
718		774
719	Alistair E. W. Johnson, Lucas Bulgarelli, Tom Pollard, Brian Gow, Benjamin Moody, Steven Horng, Leo Anthony Celi, and Roger G. Mark. 2024. MIMIC-IV (version 3.1). Accessed: 2025-05-13.	775
720		776
721		777
722		778
723		779
724	Alistair E. W. Johnson, Tom J. Pollard, and Roger G. Mark. 2022. MIMIC-IV-Note: Deidentified free-text clinical notes (version 2.2).	780
725		781
726	Jiao Li, Yueping Sun, Robin J. Johnson, Daniela Sciak, Chih-Hsuan Wei, Robert Leaman, Allan Peter Davis, Carolyn J. Mattingly, Thomas C. Wieggers, and Zhiyong Lu. 2016. Biocreative v cdr task corpus: a resource for chemical disease relation extraction. <i>Database (Oxford)</i> , 2016. Published May 9 2016; article baw068.	782
727		783
728		784
729		785
730		786
731		787
732		788
733	Yunxiang Li, Zihan Li, Kai Zhang, Ruilong Dan, Steve Jiang, and You Zhang. 2023. Chatdoctor: A medical chat model fine-tuned on a large language model meta-ai (llama) using medical domain knowledge. <i>Cureus</i> , 15(6):e40895.	789
734		790
735		791
736		792
737		793
738	Ankit Pal, Logesh Kumar Umapathi, and Malaikannan Sankarasubbu. 2022. Medmcqa: A large-scale multi-subject multi-choice dataset for medical domain question answering. In <i>Proceedings of the Conference on Health, Inference, and Learning (CHIL)</i> , volume 174 of <i>Proceedings of Machine Learning Research</i> , pages 248–260. PMLR.	794
739		795
740		796
741		797
742		798
743		799
744		800
745	Yu-Shao Peng, Kai-Fu Tang, Hsuan-Tien Lin, and Edward Chang. 2018. Refuel: Exploring sparse features in deep reinforcement learning for fast disease diagnosis. In <i>Advances in Neural Information Processing Systems</i> , volume 31. Curran Associates, Inc.	801
746		802
747		803
748		804
749		805
750	Karan Singhal, Shekoofeh Azizi, Tao Tu, S. Sara Mahdavi, Jason Wei, Hyung Won Chung, Nathan Scales, Ajay Tanwani, Heather Cole-Lewis, Stephen Pfohl, Perry Payne, Martin Seneviratne, Paul Gamble, Chris Kelly, Abubakr Babiker, Nathanael Schärli, Aakanksha Chowdhery, Philip Mansfield, Dina Demner-Fushman, and 13 others. 2023. Large language models encode clinical knowledge. <i>Nature</i> , 620(7972):172–180. Published 2023/08/01.	806
751		807
		808
		809
		810
		811
		812
		813
		814
		815
		816
		817
		818
		819
		820
		821
		822
		823
		824
		825
		826
		827
		828
		829
		830
		831
		832
		833
		834
		835
		836
		837
		838
		839
		840
		841
		842
		843
		844
		845
		846
		847
		848
		849
		850
		851
		852
		853
		854
		855
		856
		857
		858
		859
		860
		861
		862
		863
		864
		865
		866
		867
		868
		869
		870
		871
		872
		873
		874
		875
		876
		877
		878
		879
		880
		881
		882
		883
		884
		885
		886
		887
		888
		889
		890
		891
		892
		893
		894
		895
		896
		897
		898
		899
		900
		901
		902
		903
		904
		905
		906
		907
		908
		909
		910
		911
		912
		913
		914
		915
		916
		917
		918
		919
		920
		921
		922
		923
		924
		925
		926
		927
		928
		929
		930
		931
		932
		933
		934
		935
		936
		937
		938
		939
		940
		941
		942
		943
		944
		945
		946
		947
		948
		949
		950
		951
		952
		953
		954
		955
		956
		957
		958
		959
		960
		961
		962
		963
		964
		965
		966
		967
		968
		969
		970
		971
		972
		973
		974
		975
		976
		977
		978
		979
		980
		981
		982
		983
		984
		985
		986
		987
		988
		989
		990
		991
		992
		993
		994
		995
		996
		997
		998
		999
		1000